GlassScriptPhysician profile
Virginia Bonilla
NPI 1891038063
$6,110.82
in general payments reported to CMS, 2019-2025
21 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $57.96 · 2021: $575 · 2022: $614 · 2023: $1,479 · 2024: $1,460 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,189 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175 · Entertainment: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,188.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175.00 |
| Entertainment | $133.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,109.60 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $699.21 | 2019-2025 | Rocklatan, Total30, Precision 1 |
| Coopervision INC. | $506.91 | 2022-2024 | Myday Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $411.09 | 2023-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $384.77 | 2024-2025 | Xdemvy |
| Allergan, INC. | $352.77 | 2019-2022 | |
| Oyster Point Pharma, INC. | $330.25 | 2023-2024 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $281.91 | 2023-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $273.71 | 2020-2025 | Cequa |
| Glaukos Corporation | $271.74 | 2023 | |
| Harrow Eye, LLC | $237.65 | 2024-2025 | Vevye |
| Abbvie INC. | $219.84 | 2022 | |
| Optos, INC. | $218.79 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.16 | 2019 | |
| Kala Pharmaceuticals, INC. | $158.48 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $110.00 | 2022 | |
| Aerie Pharmaceuticals, INC. | $107.14 | 2021 | |
| Horizon Therapeutics Plc | $90.59 | 2023 | Tepezza |
| Amgen INC. | $77.90 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $62.51 | 2022-2023 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Bonilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.